Αρχική World News Could a Vaccine Prevent Colorectal Cancer in People with Lynch Syndrome?

Could a Vaccine Prevent Colorectal Cancer in People with Lynch Syndrome?

April 19, 2019, by NCI Staff

An immune cell (pink and red) attacks a tumor cell (blue) that makes neoantigens (blue and orange). A vaccine could help train immune cells to recognize neoantigens.

Credit: J Immunol Res 2017. doi: 10.1155/2017/5210459. CC BY 4.0.

Researchers have taken the first steps toward developing a vaccine to prevent cancer in people with Lynch syndrome, an inherited condition that elevates a person’s risk of colorectal, endometrial, and other types of cancer.

The scientists, led by Steven Lipkin, M.D., Ph.D., of Weill Cornell Medicine, reported results from NCI-funded tests of a cancer prevention vaccine at a recent meeting. The vaccine prevented the growth of colorectal tumors in a mouse model of Lynch syndrome and prolonged the mice’s survival compared with unvaccinated mice.

“The simplicity of this approach means that it is promising to take forward” to a human vaccine, Dr. Lipkin said during a press briefing April 1 at the American Association for Cancer Research annual meeting in Atlanta.

As the cost of genetic testing decreases and more people get tested for hereditary cancer syndromes, researchers are learning that Lynch syndrome is more common than once thought. It is currently estimated that 1 in every 280 Americans has the disorder, which translates to about 1.1 million people.

Current methods for preventing cancer in people with Lynch syndrome include frequent cancer screenings to detect precancer or early-stage cancer, low-dose aspirin for colorectal cancer prevention, and risk-reducing surgery.

A vaccine could offer another, potentially more efficient, way to hinder cancer development.

“The holy grail is a [cancer] cure. A holier grail is [cancer] prevention,” said cancer immunology expert Louis M. Weiner, M.D., director of Georgetown Lombardi Comprehensive Cancer Center, at the press briefing.

Shared Mutations in Lynch Syndrome Cancers

Lynch syndrome is caused by inherited gene mutations that prevent the repair of DNA errors that arise as cells divide, a defect called mismatch repair deficiency.

“It’s like not having a DNA spell-checker,” said Asad Umar, D.V.M., Ph.D., of NCI’s Division of Cancer Prevention (DCP). Without this defense, DNA errors accumulate in cells and may eventually lead to a variety of cancers.

Short repeated segments of DNA called microsatellites are especially prone to DNA mismatch errors. Tumors that are mismatch repair-deficient end up accumulating alterations in these microsatellites, a condition known as microsatellite instability.

A silver lining to microsatellite instability is that it has the potential to create novel proteins, known as neoantigens, that are unnatural to the body. Neoantigens can trigger the immune system to launch an attack on the cells that make these proteins.

What’s more, tumors that form in people with Lynch syndrome often have the same microsatellite mutations. For example, a specific microsatellite mutation in the TGFBR2 gene occurs in 60% to 80% of people with mismatch repair-deficient colorectal cancer.

Recent data suggests that some people with microsatellite instability-high cancer have evidence of an immune reaction against several of these shared neoantigens.

The presence of shared tumor neoantigens among people with Lynch syndrome “raises the possibility of being able to create a single type of vaccine that might work for millions of people,” said Dr. Weiner.

In past attempts to develop cancer vaccines, scientists used proteins that are found at higher than normal levels in cancer cells. But, because these proteins are also made by normal cells, there were concerns about unintentional side effects, Dr. Weiner pointed out.

A neoantigen-based vaccine wouldn’t have that issue, he said.

Developing and Optimizing a Cancer Vaccine

In 2011, researchers from DKFZ—the German Cancer Research Center in Heidelberg, Germany—began clinical testing of a neoantigen vaccine in people who had advanced colorectal cancer that was microsatellite instability-high.

DCP’s PREVENT Cancer Preclinical Drug Development Program, which focuses on unmet needs in cancer prevention that are not adequately addressed by the private sector, recognized the potential of this vaccine to prevent cancer in individuals with Lynch syndrome.

Dr. Lipkin, together with researchers from DKFZ, were awarded funding from the PREVENT Program to develop a cancer prevention vaccine in mice and investigate treatments that might boost its efficacy.

First, the scientists scoured DNA from 32 colorectal tumors that developed in the mouse model of Lynch syndrome and identified 13 shared mutations.

The researchers then used an algorithm to predict which of the shared mutations would create neoantigens, narrowing the number of candidates down to 10. When they injected these 10 neoantigens into mice, four triggered a strong immune response.

These four neoantigens were combined to create the mouse vaccine. Administering the vaccine plus an adjuvant in the mouse model of Lynch syndrome reduced the development of colorectal tumors and prolonged survival, they found.

“This is one of the first cancer immunoprevention vaccines that uses anticipated neoantigens that might be formed from DNA mismatch repair defects,” Dr. Umar said.

Next, the researchers determined whether combining the vaccine with other treatments could boost its efficacy.

In addition to aspirin, studies have demonstrated that naproxen (Naprosyn), a commonly used pain reliever and anti-inflammatory medication, can prevent cancer in mice. Naproxen’s potential to prevent cancer in people with Lynch syndrome is being evaluated in an ongoing NCI-funded clinical trial.

Dr. Lipkin’s team demonstrated that naproxen was better than aspirin or a control treatment at decreasing the development of colorectal tumors in the mouse model.

Naproxen also appeared to enhance the efficacy of the vaccine. Mice treated with the vaccine plus naproxen lived longer than mice that received the vaccine alone or the vaccine plus aspirin. And those in the vaccine plus naproxen group had more immune cells that recognized the vaccine neoantigens than did mice in the vaccine alone or vaccine plus aspirin groups.

Diagnosing Lynch Syndrome

People with Lynch syndrome would be candidates for a human cancer prevention vaccine, if one is developed. But less than 5% of the estimated 1.1 million people with Lynch syndrome know that they have it.

Current guidelines recommend that people with colorectal and endometrial cancer be tested for microsatellite instability. If a patient’s tumor tests positive for microsatellite instability, then it is recommended that they be tested for Lynch syndrome.

Other professional groups recommend Lynch syndrome testing for all patients diagnosed with colorectal and endometrial cancer. If Lynch syndrome is diagnosed, it is recommended that the patient’s first-degree relatives be tested for the condition as well.

Genetic testing for Lynch syndrome is often covered by insurers, including Medicare, noted Dr. Lipkin. If insurance does not cover the cost, out-of-pocket costs are about $249 or less for major genetic testing companies, he added.

However, experts agree that more needs to be done to expand genetic testing for Lynch syndrome.

Moving Toward A Human Vaccine

To develop a neoantigen vaccine for humans, Dr. Lipkin and his colleagues plan to identify shared neoantigens that occur in the early-stage colorectal tumors of people with Lynch syndrome. This project was awarded NCI funding via the Cancer MoonshotSMImmuno-Oncology Translational Network.

If human trials of a cancer prevention vaccine do move forward, Dr. Lipkin noted, it will take several years to determine whether it works.

In the meantime, his team is using the mouse model to better understand exactly how the vaccine works and ways that growing cancer cells can become resistant to its effects.



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST

Findings from an open-label, randomised, multicentre phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival...

Patients less likely to rate cancer care as ‘very good’ during pandemic

Almost a third of cancer patients have reported receiving worse care since COVID-19 began, according to a new survey commissioned by Cancer Research UK. Whilst...

How to Avoid Spreading Harmful Chemo Chemicals to Members of Your Household

Cancer is not contagious, and neither is chemotherapy. However, harmful chemotherapy drugs can sometimes still be present in the bodily fluids of a person...

Can’t Sleep? Tips for Coping with Insomnia

Insomnia* is common for cancer patients**, as well as for the general population. We frequently hear from our patients and their caregivers that sleeping through the night...

New Task Force Focuses on Quality of Life for AYAs with Cancer

August 4, 2021, by NCI Staff Adolescents and young adults are using mobile devices to document the impact of cancer and its treatment on their...

Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated NSCLC

Amivantamab demonstrated robust and durable responses in patients with epidermal growth factor receptor Exon 20 insertion (EGFR Exon20ins)-mutated non-small cell lung cancer (NSCLC) after progression on...